Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Dora Julianna SzaboDepartment of Biochemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.
Eniko TothDepartment of Biochemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.
Kitti SzaboDepartment of Biochemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0002-1177-2036
Zsofia Kata HegedusDepartment of Biochemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.
Noemi Bozsity-FaragoInstitute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0002-7907-7734
Istvan ZupkoInstitute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0003-3243-5300
Laszlo RovoDepartment of Oto-Rhino-Laryngology and Head-Neck Surgery, University of Szeged, 6720 Szeged, Hungary.
Xue XiaoQuantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lin XuQuantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-5815-4457
Aniko Keller-PinterDepartment of Biochemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0002-4105-8458
Funding
Incubation Competence Centre of the Life Sciences Cluster of the Centre of Excellence for Inter-disciplinary Research, Development and Innovation of the University of SzegedMinistry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme TKP2021-EGA-28National Academy of Scientist Education Program of the National Biomedical Foundation under the sponsorship of the Hungarian Ministry of Culture and InnovationNational Research, Development and Innovation Office of Hungary NKFI FK 134684
6 · The paper itself
Abstract
Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, arises from skeletal muscle cells that fail to differentiate terminally. Two subgroups of RMS, fusion-positive and fusion-negative RMS (FPRMS and FNRMS, respectively), are characterized by the presence or absence of the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Trastuzumab Decreases the Expression of G1/S Regulators and Syndecan-4 Proteoglycan in Human Rhabdomyosarcoma. · full record | Socratic